Msefsl

CLOSE X

Risk Disclosures on Derivatives

>9 out of 10 individual traders in equity Futures and Options Segment, incurred net losses.
>On an average, loss makers registered net trading loss close to ₹ 50,000.
>Over and above the net trading losses incurred, loss makers expended an additional 28% of net trading losses as transaction costs.
>Those making net trading profits, incurred between 15% to 50% of such profits as transaction cost.

Source:

1. SEBI study dated January 25, 2023 on “Analysis of Profit and Loss of Individual Traders dealing in equity Futures and Options (F&O) Segment”, wherein Aggregate Level findings are based on annual Profit/Loss incurred by individual traders in equity F&O during FY 2021-22.

ASTRAZENECA PHARMA INDIA LTD.

NSE : ASTRAZENBSE : 506820ISIN CODE : INE203A01020Industry : Pharmaceuticals & DrugsHouse : Astrazeneca Pharma India - MNC

BSE9093.90156.05 (+1.75 %)

PREV CLOSE ( ) 8937.85

OPEN PRICE ( ) 8966.50

BID PRICE (QTY) 9081.55 (1)

OFFER PRICE (QTY) 9096.30 (4)

VOLUME 1850

TODAY'S LOW / HIGH ( )8836.00 9170.45

52 WK LOW / HIGH ( )6222.35 10653.05

NSE9088.50162.5 (+1.82 %)

PREV CLOSE( ) 8926.00

OPEN PRICE ( ) 8926.00

BID PRICE (QTY) 9088.50 (2)

OFFER PRICE (QTY) 9089.00 (1)

VOLUME 24885

TODAY'S LOW / HIGH( ) 8825.50 9173.50

52 WK LOW / HIGH ( )6220 10691

BSE NSE

1D 1M 3M 1Y 3Y 5Y

STOCK SUMMARY

Incorporation Year : 11-07 1979

Management Info

Shilpa Divekar Nirula - Chairman - Managing Director

Registered Office

Address Block N1, 12th Floor,Manyata Embassy Business Park,Rachenahalli, Outer Ring Road,
Bengaluru,
Karnataka-560045

Phone 080 6774 8000

Email comp.secy@astrazeneca.com

Website www.astrazenecaindia.com/india

Registrars Details

Integrated Registrary Management Services Pvt Ltd.-(Formerly Integrated Enterprises (India) Ltd)

30, Ramana Residency,4th Cross, Sampige Road,Malleswaram,Bangalore

Listing : BSE, NSE

NEWS

08Aug AstraZeneca Pharma India trades higher
Astrazeneca Pharma India is currently trading at Rs. 8769.55, up by 41.0..

07Aug AstraZeneca Pharma India to launch Ecu
AstraZeneca Pharma India is all set to launch Eculizumab (Soliris) in Au..

01Aug Clarification On News Item Appearing
Please find the enclosed letter of the Company in relation to the captio..

15Jul AstraZeneca Pharma India gets nod to m
AstraZeneca Pharma India has received permission from the Central Drugs..

15Jul AstraZeneca Pharma India surges on get
Astrazeneca Pharma India is currently trading at Rs. 9378.75, up by 194...

Financials

Rs. in Millions

	QTR Jun 25	ANNUAL 25
Net Profit	558.3	1157.4
Gross Profit	747	1563.6
Operating Profit	923.5	2946
Net Sales	5263.1	17162.9

ROLLING FORWARD P/E (EOD)

EVENT CALENDAR

peer group

Neuland Laboratories (BSE) 14157.15 (3.25%)	M.Cap ( in Cr)18143.52
Abbott India (BSE) 32750.00 (1.22%)	M.Cap ( in Cr)68946.55
Glenmark Pharma (BSE) 2003.50 (4.42%)	M.Cap ( in Cr)56493.78
Ajanta Pharma (BSE) 2547.50 (2.78%)	M.Cap ( in Cr)32162.80
Lupin (BSE) 1951.20 (3.30%)	M.Cap ( in Cr)89112.81

Shareholding Pattern

	PROMOTERS	75%
	NON-INSTITUTION	17.42%
	MUTUAL FUNDS/UTI	4.33%
	FI/BANKS/INSURANCE	0.18%
	GOVERNMENT	0%
	FII	0%

Mf Holdings

Scheme Name	Hold(%)
Samco Flexi Cap Fun...	5.47
Bandhan Innovation ...	3.70
Samco Active Moment...	3.30
Baroda BNP Paribas ...	2.30
Baroda BNP Paribas ...	2.03
Samco ELSS Tax Save...	1.94
DSP Nifty Smallcap2...	1.64

Risk Disclosures on Derivatives

Smart Quotes

ASTRAZENECA PHARMA INDIA LTD.